The broad spectrum of comorbid depression: Implications for treatment

European Psychiatry

Volumn 13, Issue 1, 1998, Pages 1-8

  Mendlewicz, J ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Comorbid; Depression; SSRIs

Indexed keywords

ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DISEASE SEVERITY; HUMAN; MENTAL DISEASE; PRIORITY JOURNAL; REVIEW;

EID: 0031904891     PISSN: 09249338     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-9338(97)86745-4     Document Type: Review

References (98)

1. 1 Anderson M, Tomenson BM. The efficacy of selective serotonin re-uptake inhibitors in depression: a meta-analysis of studies against tricyclic antidepressants. J Psychopharmacol 1994 ; 8 : 238-49
2. 2 Anderson M, Tomenson BM. Treatment discontinuation with selective serotonin reuptake inhibitors compared with tricyclic antidepressants: a meta-analysis. BMJ 1995 ; 310 : 1433-8
3. 3 Baldwin D, Rudge S. The role of serotonin in depression and anxiety. Int Clin Psychopharmacol 1995 ; 9 Suppl 4 : 41-5
4. 4 Berken GH, Weinstein DO, Stern WC. Weight gain: a side-effect of tricyclic antidepressants. J Affective Disord 1984 ; 7 : 133-8
5. 5 Bowen DJ, Spring B, Fox E. Tryptophan and high-carbohydrate diets as adjuncts to smoking cessation therapy. J Behav Med 1991 ; 11 : 17-34
6. 6 Boyer W. Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta analysis. Int Clin Psychopharmacol 1995 ; 10 : 45-9
7. 7 Boyer WF. Feighner JP. Side-effects of the selective serotonin re-uptake inhibitors. In: Perspectives in Psychiatry Volume I , Selective Serotonin Re-uptake Inhibitors. Chichester: John Wiley; 1991. p 133-52
8. 8 Boyer WF, McFadden GA, Feighner JP. The efficacy of selective serotonin re-uptake inhibitors in anxiety and obsessive-compulsive disorder. In: Feighner JP, Boyer WF, eds. Perspectives in Psychiatry Volume I, Selective Serotonin Re-uptake Inhibitors. Chichester: John Wiley; 1991 ; 109-17
9. 9 Bryson HM, Wilde MI. Amitriptyline. A review of its pharmacological properties and therapeutic use in chronic pain states. Drugs Aging 1996 ; 8 : 459-76
10. 10 Carney R, Rich MW, Freedland K. Major depressive disorder predicts cardiac events in patients with coronary heart disease. Psychosom Med 1988 ; 50 : 627-33
11. 11 Cassano GB, Musetti L, Soriani A, Savino M. The pharmacologic treatment of depression: drug selection criteria. Pharmacopsychiatry 1993 ; 26 : 17-23
12. 12 Clayton PJ. The co-morbidity factor: establishing the primary diagnosis in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 1990 ; 51 Suppl : 35-9
13. 13 Coryell W, Endicott J, Andreasen NC et al. Depression and panic attacks: the significance of overlap as reflected in follow-up and family study data. Am J Psychiatry 1988 ; 145 : 293-300
14. 14 Coulehan JL, Schulberg HC, Block MR, Janosky JE, Arena VC. Medical co-morbidity of major depressive disorder in a primary medical practice. Arch Intern Med 1990 ; 150 : 2363-7
15. 15 Creed F, Ash G. Depression in rheumatoid arthritis : aetiology and treatment. Int Rev Psychiatry 1992 ; 4 : 23-34
16. 16 Cummings JL. Depression and Parkinson's disease: a review. J Clin Psychiatry 1992 ; 149 : 443-54
17. 17 Cunningham LA. Depression in the medically ill: choosing an antidepressant. J Clin Psychiatry 1994 ; 55 Suppl A : 90-7
18. 18 Dalack GW, Roose SP. Perspectives on the relationship between cardiovascular disease and affective disorder. J Clin Psychiatry 1990 ; 51 Suppl : 4-9
19. 19 Davis R, Whittington R, Bryson HM. Nefazodone. A review of its pharmacology and clinical efficacy in the management of major depression. Drugs 1997 ; 53 : 608-36
20. 20 Dunbar GC, Cohn JB, Fabre LF et al. A comparison of paroxetine, imipramine, and placebo in depressed out-patients. Br J Psychiatry 1991 ; 159 : 394-8
21. 21 Eison MS. Serotonin: a common neurobiologic substrate in anxiety and depression. J Clin Psychopharmacol 1990 ; 10 Suppl : 26-30
22. 22 Fawcett J. Targeting treatment in patients with mixed symptoms of anxiety and depression. J Clin Psychiatry 1990 ; 51 Suppl : 40-3
23. 23 Feighner JP, Boyer WF, Meredith CH, Hendrickson GG. A double-blind comparison of fluoxetine, imipramine, and placebo in outpatients with major depression. Int Clin Psychopharmacol 1989 ; 4 : 127-34
24. 24 Feighner JP, Cohn JB, Fabre LF et al. A study comparing paroxetine, placebo and imipramine in depressed patients. J Affective Disord 1993 ; 28 : 71-9
25. 25 Feighner JP. Cardiovascular safety in depressed patients: focus on venlafaxine. J Clin Psychiatry 1995 ; 56 : 574-9
26. 26 Feldman E, Mayou R, Hawton K, Smith EB. Psychiatric disorder in medical inpatients. Q J Med 1987 ; 63 : 405-12
27. 27 Fernandez F. Depression and its treatment in cardiac patients. Texas Heart Institute J 1993 ; 20 : 188-97
28. 28 Fernstrom MH, Kowinski RL, Kupfer DJ. Appetite and food preference in depression: effects of imiprimine treatment. Biol Psychiatry 1987 ; 22 : 529-39
29. 29 Fielding R. Depression and acute myocardial infarction: A review and reinterpretation. Soc Sci Med 1991 ; 32 : 1017-27
30. 30 Finkelstein SP, Weintraub RJ, Karmouz N. Anti-depressant drug treatment for post-stroke depression: retrospective study. Arch Phys Med Rehabil 1987 ; 68 : 772-6
31. 31 Fisch C. Effect of fluoxetine on the electrocardiogram. J Clin Psychiatry 1985 ; 46 : 42-4
32. 32 Frank RG, Kashani JH, Parker JC et al. Antidepressant analgesia in rheumatoid arthritis. J Rheumatol 1988 ; 15 : 1632-8
33. 33 Frasure-Smith N, Lespérance F, Talajic M. Depression following myocardial infarction: impact on 6-month survival. JAMA 1993 ; 270: 1819-25
34. 34 Classman AH, Preud'Homme XA. Review of the cardiovascular effects of heterocyclic antidepressants. J Clin Psychiatry 1993 ; 54 Suppl 2 : 16-22
35. 35 Glassman AH, Roose SP, Bigger JT Jr. The safety of tricyclic antidepressants in cardiac patients. Risk-benefit considered. JAMA 1993 ; 269 : 2673-5
36. 36 Gonzalez Torrecillas JI, Mendlewicz J, Lobo A. Effects of early treatment of poststroke depression on neuropsychological rehabilitation. Int Psychogeriatr 1995 ; 7 : 547-60
37. 37 Gonzalez Torrecillas JI, Mendlewicz J, Lobo A. Analysis of intensity of post-stroke depression and its relationship with the cerebral lesion location. Med Clin (Bare) 1997 ; 109 : 241-4
38. 38 Goodnick PJ, Henry JH, Buki VM. Treatment of depression in patients with diabetes mellitus. J Clin Psychiatry 1995 ; 56 : 128-36
39. 39 Goodnick PJ, Kumar A, Henry JH, Buki VM, Goldberg RB. Sertraline in coexisting major depression and diabetes mellitus. Psychopharmacol Bull 1997 ; 33(2) : 261-4
40. 40 Goldberg DP, Lecrubier Y. Form and frequency of mental disorders access centers. In: Üstün TB, Sartorius N. Mental illness in general health care. United Kingdom: Wiley; 1995 ; p 323-34
41. 41 Greenberg MS, Stiglin LE, Finkelstein SN, Berndt ER. Depression: a neglected major illness. J Clin Psychiatry 1993 ; 54 : 419-24
42. 42 Grunhaus L. Clinical and psychobiological characteristics of simultaneous panic disorder and major depression. Am J Psychiatry 1988 ; 145 : 1214-21
43. 43 Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the co-morbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992 ; 4 : 257-64
44. 44 Hunter B. Depression associated with rheumatoid arthritis - comparison of paroxetine and amitriptyline. Poster presented at 10th European College of Neuropsychopharmacology Congress, Vienna, Austria, September 1997
45. 45 Ibbotson T, Maguire P, Selby P, Priestman T, Wallace L. Screening for anxiety and depression in cancer patients: the effects of disease and treatment. Eur J Cancer 1994 ; 30 : 37-40
46. 46 Judge R, Steiner M. The long-term efficacy and safety of paroxetine in panic disorder. Eur Neuropsychopharmacol 1996 ; 6 suppl 3 : 207
47. 47 Kasper S, Zivkov M, Roes KC, Pols AG. Pharmacological treatment of severely depressed patients: a meta-analysis comparing efficacy of mirtazapine and amitriptyline. Eur Neuropsychopharmacol 1997 ; 7 : 115-24
48. 48 Katon W, Sullivan MD. Depression and chronic medical illness. J Clin Psychiatry 1990 ; 51 Suppl 6 : 3-11
49. 49 Katz PP, Yelin EH. Prevalence and correlates of depressive symptoms among persons with rheumatoid arthritis. J Rheumatol 1993 ; 20 : 790-6
50. 50 Keller MB, Hanks DL. Anxiety symptom relief in depression treatment outcomes. J Clin Psychiatry 1995 ; 56 Suppl 6 : 22-9
51. 51 Kessler RC, McGonagle KA, Zhao S et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch Gen Psychiatry 1994 ; 51 (1) : 8-19
52. 52 Kessler RC, Nelson CB, McGonagle KA, Liu J et al. Comorbidity of DSM-III-R major depressive disorder in the general population : results from the US National Comorbidity Survey. Br J Psychiatry 1996 ; 30 suppl : 17-30
53. 53 Le Cavorzin PH, Sarkis S, Beneton C et al. Fluvoxamine et syndrome serotoninerique chez un malade pakinsonien. Therapie 1996; 51 : 191-6
54. 54 Lecrubier Y, Bourin M, Moon CAL, Schifano F et al. Efficacy of venlafaxine in depressive illness in general practice. Acta Psychiatr Scand 1997 ; 95 : 485-93
55. 55 Lydiard RB. Co-morbidity of panic disorder, phobia and major depression. Eur Psychiatry 1995 ; 10 Suppl 2 : 65s-6s
56. 56 Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CD, Gram LF. Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man. Acta Pharmacol Toxicol (Copenhagen) 1982 ; 51 : 351-7
57. 57 McDaniel JS, Musselman DL, Porter MR, Reed DA, Nemeroff CB. Depression in patients with cancer. Diagnosis, biology and treatment. Arch Gen Psychiatry 1995 ; 52 : 89-99
58. 58 Massie MJ, Holland JC. Depression and the cancer patient. J Clin Psychiatry 1990 ; 51 Suppl : 12-7
59. 59 Mancini C, Ameringen MV. Paroxetine in social phobia. J Clin Psychiatry 1996 ; 57 : 519-22
60. 60 Mayeux R, Stern Y, Cote L, Williams JB. Altered serotonin metabolism in depressed patients with Parkinson's disease. Neurology 1984 ; 34 : 642-6
61. 61 Mayeux R, Stern Y, Williams JB, Cote L, Frantz A, Drenforth, I. Clinical and biochemical features of depression in Parkinson's disease. Am J Psychiatry 1986 ; 143 : 756-9
62. 62 Meredith L, Wells K, Camp P. Clinician speciality and treatment style for depressed outpatients with and without medical comorbidities. Arch Fam Med 1994 ; 3 : 1065-72
63. 63 Montgomery SA. SSRIs: Well tolerated treatment for depression. Hum Psychopharmacol 1994 ; 9(S1) : 7-10
64. 64 Montgomery SA, Prost JF, Solles A, Briley M. Efficacy and tolerability of milnacipran: an overview. Int Clin Psychopharmacol 1996 ; 11 suppl 4 : 47-51
65. 65 Morganroth J, Goin JE. Quinidine-related mortality in the short-to-medium-term treatment of ventricular arrhythmias: a metaanalysis. Circulation 1991 ; 84 : 1977-83
66. 66 Murphy JM, Olivier DC, Sobol AM, Monson RR, Leighton AH. Diagnosis and outcome: depression and anxiety in a general population. Psychol Med 1986 ; 16 : 117-26
67. 67 Nelson JC. Safety and tolerability of the new antidepressants. J Clin Psychiatry 1997 ; 58 suppl 6 : 26-31
68. 68 Parker JC, Wright GE. The implications of depression for pain and disability in rheumatoid arthritis. Arth Care Res 1995 ; 8 : 279-83
69. 69 Puech A, Montgomery SA, Prost JF, Solles A, Briley M. Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability. Int Clin Psychopharmacol 1997 ; 12 : 99-108
70. 70 Rechlin T. The effect of amitriptyline, doxepin, fluvoxamine, and paroxetine treatment on heart rate variability. J Clin Psychopharmacol 1994 ; 14 : 392-5
71. 71 Reding MJ, Orto LA, Winter SW, Fortuna IM, DiPonte P, McDowell FH. Anti-depressant therapy after stroke, a double-blind trial. Arch Neurol 1986 ; 43 : 763-5
72. 72 Richard IH, Kurlan R. A survey of antidepressant drug use in Parkinson's disease. Parkinson Study Group. Neurology 1997 ; 49 : 1168-70
73. 73 Rirkin A. Depression in physically ill patients. Postgrad Med 1992 ; 92 : 146-54
74. 74 Robinson DS, Roberts DL, Smith JM, Stringfellow JC et al. The safety profile of nefazodone. J Clin Psychiatry 1996 ; 57 suppl 2 : 31-8
75. 75 Roose SP, Dalack GW. Treating the depressed patient with cardiovascular problems. J Clin Psychiatry 1992 ; 53 : 25-31
76. 76 Rubin N. Severe asthma and depression. Arch Fam Med 1993 ; 12 : 433-9
77. 77 Schleifer SJ, Macari-Hinson MM, Coyle DA et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989 ; 149 : 1785-9
78. 78 Schleifer SJ, Macari-Hinson MM, Coyle DA et al. The nature and course of depression following myocardial infarction. Arch Intern Med 1989 ; 149 : 1785-9
79. 79 Schneier FR, Johnson J, Hornig CD, Liebowitz MR, Weissman MM. Social phobia: comorbidity and morbidity in an epidemiologic sample. Arch Gen Psychiatry 1992 ; 49 : 282-8
80. 80 Sommi RW, Crismon ML, Bowden CI. Fluoxetine: a serotonin specific, second generation antidepressant. Pharmacotherapy 1987 ; 7 : 1-15
81. 81 Stimmel GL, Dopheide JA, Stahl SM. Mirtazapine: an antidepressant with noradrenergic and specific serotonergic effects. Pharmacotherapy 1997 ; 17 : 10-21
82. 82 Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline [letter]. Can J Psychiatry 1990 ; 53 : 571-2
83. 83 Teri L, Wagner A. Alzheimer's disease and depression. J Consult Clin Psychiatry 1992 ; 60 : 379-91
84. 84 The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. New Engl J Med 1989 ; 321 : 406-12
85. 85 The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. New Engl J Med 1992 ; 327 : 227-33
86. 86 Tiller JWG. Post-stroke depression. Psychopharmacology 1992 ; 106 : S130-33
87. 87 Toyama SC, Iacono RP. Is it safe to combine a selective serotonin reuptake inhibitor with selegiline? Annals of Pharmacotherapy 1994 ; 28 : 405-6
88. 88 Van Loon BJP, Radder JK, Fröhlich M, Krans HM, Zwinderman AH, Meindes AE. Fluoxetine increases insulin action in obese nondiabetic and in obese non-insulin dependent diabetic individuals. Int J Obesity 1992 ; 16 : 79-85
89. 89 Verrier RL. Neurochemical approaches to the prevention of ventricular fibrillation. Fed Proc 1986 ; 45 : 2191-6
90. 90 Wallen J, Pincus HA, Goldman HH. Psychiatric consultations in short-term general hospitals. Arch Gen Psychiatry 1987 ; 44 : 163-88
91. 91 Weiss DM. Serotonin syndrome in Parkinson disease. J Am Board Family Practice 1995 ; 8 : 400-2
92. 92 Wells KB, Stewart A, Hays RD et al. The functioning and well-being of depressed patients. JAMA 1989 ; 262 : 914-9
93. 93 Wells KB, Burnham MA, Rogers W, Hays R, Camp P. The course of depression in adult outpatients. Results from the Medical Outcomes Study. Arch Gen Psychiatry 1992 ; 49 : 788-94
94. 94 Wells KB, Rogers W, Burnam MA, Camp P. Course of depression in patients with hypertension, myocardial infarction, or insulin-dependent diabetes. Am J Psychiatry 1993 ; 150 : 632-8
95. 95 Wiart L. Post-cerebrovascular stroke depression. Encephale 1997 ; 23 : 51-4
96. 96 Williams RB, Chesney MA. Psychosocial factors and prognosis in established coronary artery disease: the need for research on interventions. JAMA 1993 ; 270 : 1860-1
97. 97 Wolkow R, Apter J, Clayton A et al. Double-blind flexible dose study of sertraline and placebo in patients with panic disorder. Presented at the 20th CINP, Melbourne, Australia, June 1996
98. 98 Zohar J, Judge R and the OCD Paroxetine Study Investigators. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br J Psychiatry 1996 ; 169 : 468-74